CJC-1295 with DAC vs No DAC: Naming, Pharmacokinetics and Research Evidence
CJC-1295 is frequently discussed in two commercial formats: “with DAC” and “No DAC.” The distinction matters because the best-known published human pharmacokinetic data concern the long-acting CJC-1295 molecule developed with a Drug Affinity Complex (DAC), while the label “CJC-1295 No DAC” is used commercially for shorter-acting GHRH-related peptides and is not a standardized scientific name.
This guide focuses on nomenclature, pharmacokinetic evidence and research interpretation. It does not provide medical, therapeutic or dosing advice.
CJC-1295 with DAC: The Long-Acting Compound
CJC-1295 was developed as a long-acting analogue of growth-hormone-releasing hormone (GHRH). The DAC modification was designed to extend persistence in circulation through binding to albumin.
In a randomized, placebo-controlled study in healthy adults, a single administration of CJC-1295 produced dose-dependent increases in mean growth hormone concentrations for six days or longer and increases in IGF-I for approximately nine to eleven days. The study estimated a CJC-1295 half-life of about 5.8 to 8.1 days.
What Does “CJC-1295 No DAC” Mean?
“CJC-1295 No DAC” is widely used as a commercial peptide label, but researchers should be careful with the terminology. Shorter-acting GHRH analogues are also described in the literature as modified GRF(1-29), and commercial naming is not always consistent across suppliers.
A forensic analytical paper, for example, identified modified GRF(1-29) separately from other growth-hormone secretagogues in seized materials. This highlights why the exact chemical identity should be verified from the product specification and analytical documentation rather than inferred only from a retail name.
Key Research Differences
| Feature | CJC-1295 with DAC | Products labelled “CJC-1295 No DAC” |
|---|---|---|
| Scientific naming | CJC-1295 long-acting GHRH analogue | Commercial label; often associated with shorter-acting modified GHRH/GRF analogues |
| Direct human pharmacokinetic evidence | Published randomized human data are available | Do not assume the CJC-1295 DAC pharmacokinetic data apply to a different molecule |
| Duration evidence | Published study estimated a 5.8–8.1 day half-life | Depends on the exact chemical identity; verify the compound rather than relying on the label |
| Research-documentation priority | Confirm sequence/identity, strength and analytical documentation for the actual product being studied. | |
Why the Naming Distinction Matters
Using the published CJC-1295 DAC half-life or endocrine-response data to describe every product sold as “CJC-1295” can blur an important chemical distinction. A research protocol should be based on the identity of the actual compound, not solely on a marketing shorthand.
For the same reason, comparisons between DAC and No-DAC products should focus on verified structure and analytical documentation before drawing conclusions from literature generated with another analogue.
CJC-1295 Product Formats at Peps In Bulk
Peps In Bulk lists CJC-1295 with DAC and CJC-1295 No DAC as separate research products. Current strength options, AUD pricing and available documentation are shown on the individual product pages. Related products can be found in the growth research category.
Selected Published References
- Teichman et al. — prolonged GH and IGF-I stimulation by CJC-1295 in healthy adults.
- Forensic identification of modified GRF(1-29) and other growth-hormone secretagogues.
Research information only. This article does not provide medical, therapeutic or dosing advice.